Engineered cellular immunotherapies in cancer and beyond.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35440724.
- Also identified by DOI 10.1038/s41591-022-01765-8 and PMC identifier 9305718.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-modified T cells for refractory leukemia. The widespread commercial approval of genetically engineered T cells for a variety of blood cancers offers hope for patients with other types of cancer, and the convergence of human genome engineering and cell therapy technology holds great potential for generation of a new class of cellular therapeutics. In this Review, we discuss the goals of cellular immunotherapy in cancer, key challenges facing the field and exciting strategies that are emerging to overcome these obstacles. Finally, we outline how developments in the cancer field are paving the way for cellular immunotherapeutics in other diseases.
Medical subject headings
- Neoplasms
- Receptors, Chimeric Antigen